Large animal models of rare genetic disorders: Sheep as phenotypically relevant models of human genetic disease

Orphanet Journal of Rare Diseases

Volumn 10, Issue 1, 2015, Pages

  Pinnapureddy, Ashish R ^a   Stayner, Cherie ^a   McEwan, John ^b   Baddeley, Olivia ^c   Forman, John ^c   Eccles, Michael R ^a,d  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b INVERMAY AGRICULTURAL CENTRE   (New Zealand)

^c New Zealand Institute for Water and Atmospheric Research Ltd   (New Zealand)

^d MAURICE WILKINS CENTRE FOR MOLECULAR BIODISCOVERY   (New Zealand)

Author keywords

DNA sequencing; genetic disease; human genome; Large animal model; ovine genome; sheep

Indexed keywords

BODY SIZE; CLN6 GENE; GAUCHER DISEASE; GENE; GENE SEQUENCE; GENETIC DISORDER; GENETIC VARIABILITY; GENOME ANALYSIS; HUMAN; LONGEVITY; MECKEL SYNDROME; NEURONAL CEROID LIPOFUSCINOSIS; NEXT GENERATION SEQUENCING; NONHUMAN; OVINE MODEL; PHENOTYPE; RARE DISEASE; REVIEW; TAY SACHS DISEASE; ANIMAL; DISEASE MODEL; GENETICS; HIGH THROUGHPUT SEQUENCING; SHEEP;

ANIMALS; DISEASE MODELS, ANIMAL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PHENOTYPE; RARE DISEASES; SHEEP;

EID: 84940570535     PISSN: None     EISSN: 17501172     Source Type: Journal    
DOI: 10.1186/s13023-015-0327-5     Document Type: Review

References (65)

1. Barnetche T, Gourraud PA, Cambon-Thomsen A. Strategies in analysis of the genetic component of multifactorial diseases; biostatistical aspects. Transpl Immunol. 2005;14:255-66.
2. Thorisson GA, Smith AV, Krishnan L, Stein LD. The International HapMap Project Web site. Genome Res. 2005;15:1592-3.
3. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine (Baltimore MD). Online Mendelian Inheritance of Man, OMIM®. http://www.ncbi.nlm.nih.gov/omim). Accessed 21 March 2014.
4. Maxmen A. Exome sequencing deciphers rare diseases. Cell. 2011;144:635-7.
5. Gahl WA, Markello TC, Toro C, Fajardo KF, Sincan M, Gill F, et al. The national institutes of health undiagnosed diseases program: insights into rare diseases. Genet Med. 2012;14:51-9.
6. Stevens CA, Sargent LA. Ablepharon-macrostomia syndrome. Am J Med Genet. 2002;107:30-7.
7. Antonarakis SE, Beckmann JS. Mendelian disorders deserve more attention. Nat Rev Genet. 2006;7:277-82.
8. New Zealand Institute for Rare Disease Research; animal models database. http://www.nzirdr.org.nz/animal-models/our-models. Accessed March 21, 2014.
9. Frugier T, Mitchell NL, Tammen I, Houweling PJ, Arthur KG, Kay GW, et al. A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571∈+∈1G∈>∈A) leading to excision of exon 3. Neurobiol Dis. 2008;29:306-15.
10. Zarrinkalam MR, Beard H, Schultz CG, Moore RJ. Validation of the sheep as a large animal model for the study of vertebral osteoporosis. Eur Spine J. 2009;18:244-53.
11. Thyagarajan T, Totey S, Danton MJ, Kulkarni AB. Genetically altered mouse models: the good, the bad, and the ugly. Crit Rev Oral Biol Med. 2003;14:154-74.
12. Beal MF, Ferrante RJ. Experimental therapeutics in transgenic mouse models of Huntington's disease. Nat Rev Neurosci. 2004;5:373-84.
13. Seidl SE, Potashkin JA. The promise of neuroprotective agents in Parkinson's disease. Front Neurol. 2011;2:68.
14. Xu Q, Shenoy S, Li C. Mouse models for LRRK2 Parkinson's disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S186-9.
15. Wilson PD. Mouse models of polycystic kidney disease. Curr Top Dev Biol. 2008;84:311-50.
16. Jacenko O, Olsen BR. Transgenic mouse models in studies of skeletal disorders. J Rheumatol Suppl. 1995;43:39-41.
17. Hersch SM, Ferrante RJ. Translating therapies for Huntington's disease from genetic animal models to clinical trials. NeuroRx. 2004;1:298-306.
18. Seok J, Warren HS, Cuenca AG, Mindrino MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507-12.
19. Wilmut I, Sullivan G, Taylor J. A decade of progress since the birth of Dolly. Reprod Fertil Dev. 2009;21:95-100.
20. Rezapour M, Novara G, Meier PA, Holste J, Landgrebe S, Artibani W. A 3-month preclinical trial to assess the performance of a new TVT-like mesh (TVTx) in a sheep model. Int Urogynecol J Pelvic Floor Dysfunct. 2007;18:183-7.
21. Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Discov. 2013;12:569.
22. Tammen I, Houweling PJ, Frugier T, Mitchell NL, Kay GW, Cavanagh JA, et al. A missense mutation (c.184C∈>∈T) in ovine CLN6 causes neuronal ceroid lipofuscinosis in Merino sheep whereas affected South Hampshire sheep have reduced levels of CLN6 mRNA. Biochim Biophys Acta. 2006;1762:898-905.
23. Cummings JF, Wood PA, Walkley SU, de Lahunta A, DeForest ME. GM2 gangliosidosis in a Japanese spaniel. Acta Neuropathol. 1985;67:247-53.
24. Karbe E, Schiefer B. Familial amaurotic idiocy in male German shorthair pointers. Pathol Vet. 1967;4:223-32.
25. Cork LC, Munnell JF, Lorenz MD. The pathology of feline GM2 gangliosidosis. Am J Pathol. 1978;90:723-34.
26. Cork LC, Munnell JF, Lorenz MD, Murphy JV, Baker HJ, Rattazzi MC. GM2 ganglioside lysosomal storage disease in cats with beta-hexosaminidase deficiency. Science. 1977;196:1014-7.
27. Hasegawa D, Yamato O, Kobayashi M, Fujita M, Nakamura S, Takahashi K, et al. Clinical and molecular analysis of GM2 gangliosidosis in two apparent littermate kittens of the Japanese domestic cat. J Feline Med Surg. 2007;9:232-7.
28. Neuwelt EA, Johnson WG, Blank NK, Pagel MA, Maslen-McClure C, McClure MJ, et al. Characterization of a new model of GM2-gangliosidosis (Sandhoff's disease) in Korat cats. J Clin Invest. 1985;76:482-90.
29. Kosanke SD, Pierce KR, Bay WW. Clinical and biochemical abnormalities in porcine GM2-gangliosidosis. Vet Pathol. 1978;15:685-99.
30. Pierce KR, Kosanke SD, Bay WW, Bridges CH. Animal model of human disease: GM2 gangliosidosis. Am J Pathol. 1976;83:419-22.
31. Read WK, Bridges CH. Cerebrospinal lipodystrophy in swine. A new disease model in comparative pathology. Pathol Vet. 1968;5:67-74.
32. Gun G, Kues WA. Current progress of genetically engineered pig models for biomedical research. Biores Open Access. 2014;3:255-64.
33. Schoenebeck JJ, Ostrander EA. Insights into morphology and disease from the dog genome project. Annu Rev Cell Dev Biol. 2014;30:535-60.
34. Palmer DN, Neverman NJ, Chen JZ, Chang CT, Houweling PJ, Barry LA, et al. Recent studies of ovine neuronal ceroid lipofuscinoses from BARN, the Batten Animal Research Network. Biochim Biophys Acta. 2015.
35. Roth JA, Tuggle CK. Livestock models in translational medicine. ILAR J. 2015;56:1-6.
36. Agerholm JS. Inherited disorders in Danish cattle. APMIS Suppl. 2007;1-76.
37. Morton JD, Lee HY, McDermott JD, Robertson JJ, Bickerstaffe R, Jones MA, et al. A macrocyclic calpain inhibitor slows the development of inherited cortical cataracts in a sheep model. Invest Ophthalmol Vis Sci. 2013;54:389-95.
38. Banin E, Gootwine E, Obolensky A, Ezra-Elia R, Ejzenberg A, Zelinger L, et al. Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia. Mol Ther. 2015.
39. Porada CD, Sanada C, Long CR, Wood JA, Desai J, Frederick N, et al. Clinical and molecular characterization of a re-established line of sheep exhibiting hemophilia A. J Thromb Haemost. 2010;8:276-85.
40. Porada CD, Sanada C, Kuo CJ, Colletti E, Mandeville W, Hasenau J, et al. Phenotypic correction of hemophilia A in sheep by postnatal intraperitoneal transplantation of FVIII-expressing MSC. Exp Hematol. 2011;39:1124-35. e4.
41. Luhken G. Genetic testing for phenotype-causing variants in sheep and goats. Mol Cell Probes. 2012;26:231-7.
42. Tan P, Allen JG, Wilton SD, Akkari PA, Huxtable CR, Laing NG. A splice-site mutation causing ovine McArdle's disease. Neuromuscul Disord. 1997;7:336-42.
43. Rider JA, Rider DL. Batten disease: past, present, and future. Am J Med Genet. 1988;5:21-6.
44. MRC Laboratory for Molecular Cell Biology and London. UC NCL RESOURCE - A GATEWAY FOR BATTEN DISEASE NCL Mutation and Patient Database. http://www.ucl.ac.uk/ncl/mutation.shtml. accessed August 2015.
45. Jolly RD, Janmaat A, West DM, Morrison I. Ovine ceroid-lipofuscinosis: a model of Batten's disease. Neuropathol Appl Neurobiol. 1980;6:195-209.
46. Jolly RD, Palmer DN. The neuronal ceroid-lipofuscinoses (Batten disease): comparative aspects. Neuropathol Appl Neurobiol. 1995;21:50-60.
47. Palmer DN, Tammen I, Drogemuller C, Johnson GS, Katz ML, Lingaas F. Large animal models in: SE Mole, RE Williams, HH Goebel (Eds) The Neuronal Ceroid Lipofuscinoses (Batten Disease), 2nd edition, Oxford University Press Inc, New York. 2011:pp. 284-320.
48. Bond M, Holthaus SM, Tammen I, Tear G, Russell C. Use of model organisms for the study of neuronal ceroid lipofuscinosis. Biochim Biophys Acta. 1832;2013:1842-65.
49. Torres PA, Zeng BJ, Porter BF, Alroy J, Horak F, Horak J, et al. Tay-Sachs disease in Jacob sheep. Mol Genet Metab. 2010;101:357-63.
50. Porter BF, Lewis BC, Edwards JF, Alroy J, Zeng BJ, Torres PA, et al. Pathology of G(M2) Gangliosidosis in Jacob Sheep. Vet Pathol. 2011;48:807-13.
51. Kolodny EH, Brady RO, Volk BW. Demonstration of an alteration of ganglioside metabolism in Tay-Sachs disease. Biochem Biophys Res Commun. 1969;37:526-31.
52. Kolter T, Sandhoff K. Glycosphingolipid degradation and animal models of GM2-gangliosidoses. J Inherit Metab Dis. 1998;21:548-63.
53. Karageorgos L, Lancaster MJ, Nimmo JS, Hopwood JJ. Gaucher disease in sheep. J Inherit Metab Dis. 2011;34:209-15.
54. Enquist IB, Nilsson E, Ooka A, Mansson JE, Olsson K, Ehinger M, et al. Effective cell and gene therapy in a murine model of Gaucher disease. Proc Natl Acad Sci U S A. 2006;103:13819-24.
55. Xu YH, Quinn B, Witte D, Grabowski GA. Viable mouse models of acid beta-glucosidase deficiency - The defect in Gaucher disease. Am J Pathol. 2003;163:2093-101.
56. Sandison AT, Anderson LJ. Histiocytosis in 2 Pigs and a Cow - Conditions Resembling Lipid Storage Disorders in Man. J Pathol. 1970;100:207-10.
57. Laws L, Saal JR. Lipidosis of Hepatic Reticulo-Endothelial Cells in a Sheep. Aust Vet J. 1968;44:416-7.
58. Beutler E, Gelbart T, Scott CR. Hematologically important mutations: Gaucher disease. Blood Cells Mol Dis. 2005;35:355-64.
59. Logan CV, Abdel-Hamed Z, Johnson CA. Molecular genetics and pathogenic mechanisms for the severe ciliopathies: insights into neurodevelopment and pathogenesis of neural tube defects. Mol Neurobiol. 2011;43:12-26.
60. Wang XF, Li M, Qian Q, Harris PC, Torres VE. Effects of amiloride in two animal models of polycystic kidney disease (PKD). J Am Soc Nephrol. 2002;13:509A-A.
61. Johnstone AC, Davidson BI, Roe AR, Eccles MR, Jolly RD. Congenital polycystic kidney disease in lambs. N Z Vet J. 2005;53:307-14.
62. Gunay-Aygun M, Parisi MA, Doherty D, Tuchman M, Tsilou E, Kleiner DE, et al. MKS3-Related Ciliopathy with Features of Autosomal Recessive Polycystic Kidney Disease, Nephronophthisis, and Joubert Syndrome. J Pediatr. 2009;155:386-92.
63. Jiang Y, Xie M, Chen W, Talbot R, Maddox JF, Faraut T, et al. The sheep genome illuminates biology of the rumen and lipid metabolism. Science. 2014;344:1168-73.
64. Barzon L, Lavezzo E, Militello V, Toppo S, Palu G. Applications of Next-Generation Sequencing Technologies to Diagnostic Virology. Int J Mol Sci. 2011;12:7861-84.
65. Childers CP, Reese JT, Sundaram JP, Vile DC, Dickens CM, Childs KL, et al. Bovine Genome Database: integrated tools for genome annotation and discovery. Nucleic Acids Res. 2011;39:D830-4.